Research Grade Blinatumomab ( 兰妥莫单抗 )
- 发布日期： 2020-10-28
- 更新日期： 2025-10-28
产品详请
| 产地 |
中国
|
| 品牌 |
Chemstan
|
| 货号 |
CSD00035
|
| 保存条件 |
store at -80℃
|
| 用途 |
仅用于科研用途
|
| 应用范围 |
|
| 抗原来源 |
CHO cells
|
| CAS编号 |
853426-35-4
|
| 保质期 |
一年
|
| 抗体名 |
Blinatumomab ( 兰妥莫单抗 )
|
| 是否单克隆 |
|
| 克隆性 |
|
| 靶点 |
CD19/CD3E[Homo sapiens]
|
| 适应物种 |
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
mg/ml
|
| 纯度 |
%
|
| 亚型 |
|
| 标识物 |
|
| 浓度 |
95%
|
| 免疫原 |
|
| 是否进口 |
否
|
货号（Catalog No.）
CSD00035
通用名INN
Blinatumomab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).Blinatumomab is manufactured by Amgen Inc.and marketed under the brand Blincyto.Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program,which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.
别名(Alternative names)
AMG103,BITE MT-103,MEDI-538,MT103,bscCD19xCD3
靶点;物种(Specificity target name;species)
CD19/CD3E[Homo sapiens]
种类(Species)
Mus musculus
受体鉴定(Receptor identification)
(scFv-kappa-heavy)-(scFv-heavy-kappa)
化学信息
分子量(MV)
54100.00 Da
CAS
853426-35-4
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
